JP2023522208A5 - - Google Patents
Info
- Publication number
- JP2023522208A5 JP2023522208A5 JP2022562984A JP2022562984A JP2023522208A5 JP 2023522208 A5 JP2023522208 A5 JP 2023522208A5 JP 2022562984 A JP2022562984 A JP 2022562984A JP 2022562984 A JP2022562984 A JP 2022562984A JP 2023522208 A5 JP2023522208 A5 JP 2023522208A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- during
- composition according
- week
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010905P | 2020-04-16 | 2020-04-16 | |
| US63/010,905 | 2020-04-16 | ||
| US202063014999P | 2020-04-24 | 2020-04-24 | |
| US63/014,999 | 2020-04-24 | ||
| US202063019050P | 2020-05-01 | 2020-05-01 | |
| US63/019,050 | 2020-05-01 | ||
| US202063020286P | 2020-05-05 | 2020-05-05 | |
| US202063020195P | 2020-05-05 | 2020-05-05 | |
| US63/020,286 | 2020-05-05 | ||
| US63/020,195 | 2020-05-05 | ||
| US202063033140P | 2020-06-01 | 2020-06-01 | |
| US63/033,140 | 2020-06-01 | ||
| US202063063538P | 2020-08-10 | 2020-08-10 | |
| US63/063,538 | 2020-08-10 | ||
| PCT/US2021/027636 WO2021211940A1 (en) | 2020-04-16 | 2021-04-16 | Methods for treating a complement mediated disorder caused by viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522208A JP2023522208A (ja) | 2023-05-29 |
| JP2023522208A5 true JP2023522208A5 (https=) | 2024-09-09 |
Family
ID=75787341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562984A Pending JP2023522208A (ja) | 2020-04-16 | 2021-04-16 | ウイルスによって引き起こされる補体媒介性障害を処置する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230416344A1 (https=) |
| EP (1) | EP4135837A1 (https=) |
| JP (1) | JP2023522208A (https=) |
| CN (1) | CN116406287A (https=) |
| WO (1) | WO2021211940A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| KR20220110827A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체 |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| WO2022036151A1 (en) * | 2020-08-13 | 2022-02-17 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| WO2024121370A1 (en) * | 2022-12-09 | 2024-06-13 | Universität Zürich | Complement component 7 as a diagnostic marker and therapeutic target |
| US12180274B2 (en) * | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| WO2025221479A1 (en) * | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| MX340696B (es) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CA2940319A1 (en) * | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| KR102806328B1 (ko) | 2017-07-11 | 2025-05-14 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| US20200230408A1 (en) * | 2018-12-21 | 2020-07-23 | Electrocore, Inc. | Systems and methods for treating patients with diseases associated with replicating pathogens |
| WO2019227102A1 (en) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| EP3852874A1 (en) * | 2018-09-17 | 2021-07-28 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
-
2021
- 2021-04-16 EP EP21723594.4A patent/EP4135837A1/en active Pending
- 2021-04-16 US US17/918,863 patent/US20230416344A1/en active Pending
- 2021-04-16 JP JP2022562984A patent/JP2023522208A/ja active Pending
- 2021-04-16 WO PCT/US2021/027636 patent/WO2021211940A1/en not_active Ceased
- 2021-04-16 CN CN202180043318.6A patent/CN116406287A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023522208A5 (https=) | ||
| US11325972B2 (en) | Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody | |
| Bagshaw et al. | The effect of low-dose furosemide in critically ill patients with early acute kidney injury: a pilot randomized blinded controlled trial (the SPARK study) | |
| JP2020183389A5 (https=) | ||
| JP5954916B1 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| US20220151581A1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| KR20170015517A (ko) | 혈액 응고 제 viii 인자 및/또는 활성화 혈액 응고 제 viii 인자의 활성의 저하 내지 결손에 의해 발증 및/또는 진전되는 질환의 예방 및/또는 치료에 이용되는 의약 조성물 | |
| JP2023528441A5 (https=) | ||
| JP2021525718A5 (https=) | ||
| US20240209097A1 (en) | Treatment regimens | |
| EP4493588A1 (en) | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment | |
| Ware et al. | TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial | |
| TW202124454A (zh) | 抗ｐｃｓｋ９抗體用於預防或治療膽固醇相關疾病的方法 | |
| WO2019089147A1 (en) | Methods of treating didiopathic pulmonary fibrosis | |
| JP2023521909A (ja) | 呼吸器疾患の治療 | |
| Khoshfetrat et al. | A Comparison of Premedication Injections of Magnesium Sulfate, Ketamine and Lidocaine on the severity of Pain Induced by Intravenous Injection of Propofol | |
| KR20220167289A (ko) | 사이토카인 폭풍 증후군의 치료를 위한 펩타이드 | |
| WO2019025847A1 (en) | TREATMENT DIAGRAMS | |
| WO2021185832A1 (en) | New therapeutic treatment | |
| Kim et al. | The comparative effects of S-amlodipine versus racemic amlodipine on long-term cardiovascular outcomes in subjects with hypertension: a nationwide population-based cohort study | |
| WO2021185838A1 (en) | New therapeutic use of anakinra for covid-19 | |
| WO2025238225A1 (en) | Methods of treating osteoarthritis and osteoarthritis pain with an anti complement c2 antagonistic antibody | |
| WO2021207667A1 (en) | Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards) | |
| Lang et al. | Management of comorbidities in heart failure | |
| Lang et al. | in Heart Failure |